The synthetic double-stranded RNA poly(I:C) is commonly used as an adjuvant to boost CD8 T-cell function; however, polyinosinic: polycytidylic acid [poly(I:C)] can also suppress autoimmune disease. The mechanism by which a single adjuvant achieves two distinct immunoregulatory roles is unknown. Although it is clear that coadministration of poly(I:C) with antigen elicits strong adjuvant effects in mice, we found that poly(I:C) injection before antigen substantially reduced antigen-dependent CD8 T-cell responses. Notably, CD8 T cells sensitized in poly(I:C)-pretreated mice failed to fully up-regulate IL-33R (ST2), which led to impaired T-cell receptorindependent responses to IL-33. In contrast, nonsensitized effector CD8 T cells responded robustly to IL-33 using a two-signal cytokine mechanism. During an acute lung response to Staphylococcus aureus enterotoxin, peripheral injection of poly(I:C) manifested a suppressive process by inhibiting the differentiation of both antigen-and IL-33-responsive CD8 effectors systemically. These findings highlight that early exposure to double-stranded RNA reverses its role as an adjuvant and, importantly, prevents IL-33R up-regulation on CD8 effector T cells to dampen inflammation.
superantigens | pathogen associated molecular patterns P olyinosinic:polycytidylic acid [poly(I:C)] is a synthetic doublestranded RNA (dsRNA) that is widely used to mimic the biological effects of dsRNA viruses and viral replication products. Immune responses to poly(I:C) are mediated by several known dsRNA receptors, some of which reside intracellularly (MDA5, RIG-I, and LGP2) and others of which are found on the endosomal membrane (TLR3) (reviewed in ref. 1) . Poly(I:C) activates TLR3 and MDA5, which trigger the production of proinflammatory cytokines and IFN responses (2, 3) . The potent effects of the synthetic dsRNA poly(I:C) on CD8 T-cell activation is well appreciated and used for tumor eradication (4) . Poly(I:C) induces dendritic cell maturation, and it facilitates antigen cross-priming through the TLR3 pathway (5) . Furthermore, cytokine production in response to poly(I:C) plays a crucial role in priming the T-cell response. In this regard, multiple studies have demonstrated that induction of type I IFN is indispensable for the poly(I:C)-dependent augmentation of CD8 T-cell function (6) (7) (8) .
The immune-enhancing aspects of TLR ligands, including poly (I:C), have been extensively investigated (reviewed in ref. 9); however, evidence suggests that TLR ligands can also block responses. Poly(I:C) was shown to inhibit autoimmune diseases (10, 11) . Additionally, when given prophylactically, poly(I:C) can prevent autoimmune diabetes in mice and in rat strains that are genetically susceptible to the disease (12, 13) . In retrospect, these results are fascinating considering that CD8 T cells are pathological mediators in autoimmune diabetes (14) . In contrast, other reports using different models of diabetes found that poly(I:C) potentiates or exacerbates disease, consistent with poly(I:C)'s known adjuvant effects (15) (16) (17) (18) . On the basis of these reports, we reasoned that the seemingly contradictory roles of poly(I:C) during autoimmune diabetes development may be related to its differential influence on effector CD8 T cells.
We demonstrate that poly(I:C) could promote or suppress the T-cell receptor (TCR) response to a cognate antigen depending on the timing of poly(I:C) injection. Prophylactic poly(I:C) stimulation weakened CD8 T-cell expansion and effector differentiation, dampening sensitivity to antigen restimulation. The weakened effector CD8 T cells did not up-regulate the IL-33 receptor α (ST2) chain as did conventional effector CD8 T cells. Even though the IL-33 pathway has been historically associated with Th2 responses, we found that the effector CD8 T cells responded vigorously to IL-33, IL-2, or IL-12 by synthesizing prodigious IFNγ levels. The mechanism of this process involved a two-signal sequence that first required IL-12 followed by IL-33 for the induction of IFNγ synthesis. Finally, systemic injection of poly(I:C) manifested suppression in response to acute lung injury by limiting local IL-5 and the differentiation of antigen-and IL-33-responsive effector CD8 T cells in the periphery. These findings suggest that responses to poly(I:C) before onset of inflammatory-based diseases may be beneficial by preventing excessive T-cell activation and that one point of control is the IL-33 receptor pathway.
Results
Systemic Pretreatment with the dsRNA Poly(I:C) Suppresses AntigenSpecific CD8 T-Cell Responses. Poly(I:C) coadministration with antigen elicits potent adjuvant effects on CD8 T cells (7, 19) . In contrast, we observed that poly(I:C) injected before antigen encounter [poly(I:C) 3 d before antigen immunization] can suppress CD8 T-cell expansion ( Fig. 1 A-C) . This effect was first observed using adoptively transferred CD8 T cells (OT-I cells) that can be traced by costaining the congenic marker CD45.1 and the TCR Vα2 chain (Fig. S1A ). In the absence of adjuvant, the response of OT-I CD8 T cells toward their cognate antigen, SIINFEKL (an ovalbumin-derived, class I-restricted peptide), constituted ∼16% of the total splenic CD8 T-cell population on day 3 (Fig. S1A) . Overall numbers of activated OT-I CD8 T cells decreased significantly in spleen, liver, and lung of poly(I:C)-pretreated recipients, indicating a systemic effect on CD8 T-cell expansion in both secondary and tertiary lymphoid organs (Fig. 1A) . Phenotypic analysis revealed that the majority of the OT-I CD8 T cells primed in poly(I:C)-pretreated mice remained CD62L-high and had slightly lower CXCR3 expression compared with their counterparts in control-treated mice (Fig. 1D) , indicating a less activated status for these cells. Specifically, poly(I:C) pretreatment resulted in only 36 ± 7% of CD62L lo OT-I CD8 T cells compared with 59 ± 6% in control-treated mice (P = 0.041, n > 6 from four independent experiments).
To test the robustness of this finding, we adapted this to a system that uses staphylococcal enterotoxin A (SEA) to activate endogenous T cells. In this system, the fate of antigen-specific CD8 or CD4 T cells is followed by staining for Vβ3 + cells (Fig.  S1B ). Poly(I:C) treatment before SEA immunization significantly decreased the number of CD8 +
Vβ3
+ T cells compared with control-treated animals (Fig. 1B, Left) whereas coadministration of poly(I:C) with SEA on day 0 demonstrated its adjuvant effect (Fig. 1B, Left) . A similar trend was observed with SEA-specific CD4 T cells (Fig. 1B, Right) .
Suppression by poly(I:C) pretreatment was further demonstrated with endogenous ovalbumin-specific CD8 T cells. Endogenous CD8 T cells responding to SIINFEKL peptide coadministered with the adjuvant CpG and the agonist antibody targeting the 4-1BB costimulatory molecule can be detected by tetramer-staining on day 6 post immunization ( Fig. S1C ). Mice that were pretreated with poly(I:C) demonstrated significantly weaker CD8 T-cell expansion (Fig. 1C) . Altogether, we showed that pre-exposure to poly(I:C) resulted in suboptimal expansion of both adoptively transferred ( Fig. 1A) and endogenous ( Fig. 1 B and C) CD8 T cells. This observation is true for CD8 T cells activated by antigen alone (Fig. 1A) , with CD4 T-cell help (Fig. 1B) , or in the presence of adjuvant with costimulation ( Fig. 1C) .
We next investigated if poly(I:C) pretreatment impacts differentiation of CD8 T cells into cytotoxic effectors. Effector differentiation (indicated by the frequency of IFNγ and TNF double producers within OT-I cells) was reduced by close to half in the poly(I:C)-pretreated hosts (Fig. 1E , Upper Right). Enumeration of IFNγ and TNF double producers in spleen and liver revealed that the total number of such CD8 effectors decreased by 4.4-and 6.5-fold, respectively (Fig. S2A ). Granzyme B was substantially reduced in poly(I:C)-pretreated mice (Fig. 1F ). Throughout spleen, liver, and lung, the mean fluorescence intensity of granzyme B staining decreased by 42 ± 6%. Importantly, OT-I CD8 T cells from poly(I:C)-pretreated mice displayed significantly less degranulation, as measured by CD107 expression when restimulated with peptide ex vivo compared with controltreated mice (Fig. S2B) . Hence, poly(I:C) could suppress both the magnitude of T-cell expansion and the quality of the cytotoxic effectors formed.
Poly(I:C) Pretreatment Suppresses TCR-Independent Effector Function
of Activated CD8 T cells by Impeding the IL-33 Pathway. To uncover differences between CD8 T cells primed in control and poly(I:C)-pretreated mice, OT-I CD8 T cells were sorted from spleens and subjected to genechip analysis. Results from two separate experiments showed that ST2, which is the IL-33 receptor α-chain that binds IL-33 as its ligand (20), was not up-regulated on OT-I CD8 T cells from poly(I:C)-pretreated mice (Fig. S3 ). IL-33/ST2 signaling is known to drive Th2 responses (20) , induce effector cytokine secretion from human mast cells and eosinophils (21, 22) , and synergize with IL-18, IL-12, and IL-23 to induce IFNγ from NK cells (23) and is required for protective antiviral responses (24) .
To validate our genechip data, surface ST2 staining was tested on activated CD8 T cells ( Fig. 2A, Left) . After in vivo immunization with SIINFEKL peptide, an average of 3% of day 3-activated OT-I CD8 T cells (CD45.1 + ) express surface ST2 ( Fig. 2A,  Right) . Consistent with the genechip data, ST2 protein expression was significantly reduced when the OT-I CD8 T cells were primed in poly(I:C)-pretreated mice ( Fig. 2A) . Importantly, upon ex vivo restimulation with peptide antigen, day 3-activated OT-I CD8 T cells that were previously not ST2 + rapidly up-regulated ST2 (Fig. 2B) . OT-I CD8 T cells primed in poly(I:C)-pretreated mice have much reduced capacity to express ST2 upon restimulation (Fig. 2B) .
We reasoned that ST2 expression on activated CD8 T cells might enable these cells to respond to IL-33 stimulation. It was recently reported that in vitro-differentiated type I cytotoxic T cells (Tc1 cells) express ST2 and respond synergistically to IL-33 and IL-12 stimulation to produce IFNγ (25) . Extending this observation to in vivo-activated CD8 T cells, we found that purified day 3 OT-I CD8 T cells responded to the combined action of IL-33 and IL-12 to produce prodigious levels of IFNγ (Fig. 3A) . On the other hand, naive OT-I CD8 T cells did not respond to the combined action of these cytokines (Fig. 3A) . In a different set of experiments, day 3-activated OT-I CD8 T cells were FACS-sorted to prevent inclusion of contaminating cells that might respond to IL-33 (Fig. S4A) . We discovered that, in addition to IL-12, IL-33 also synergized with IL-2 to induce IFNγ from activated CD8 T cells (Fig. 3B) . Under both conditions, OT-I CD8 T cells activated in poly(I:C)-pretreated mice responded poorly to IL-33 + IL-12 or IL-2 stimulation (Fig. 3 A and B) , consistent with the down-regulation of ST2 on these T cells. To further validate that IFNγ was indeed produced by CD8 T cells, brefeldin A was added during the last 5 h of the 24-h ex vivo culture to trap the cytokine intracellularly (Fig. S4B) . We observed that ∼2% of OT-I CD8 T cells are the source of IFNγ whereas TNF, another effector cytokine that is commonly induced alongside IFNγ during TCR restimulation, was not induced by IL-33 + IL-12 (Fig. S4B) . As a negative control, IL-18 was tested, and we showed that IL-33 displayed no synergistic effects when cocultured with IL-18 (Fig. S4B) . Therefore, IL-33 selectively cooperates with certain cytokines to trigger the TCR-independent effector function of CD8 T cells. Poly(I:C) pretreatment in the host impairs this aspect of T-cell effector differentiation by inhibiting ST2 expression on the activated CD8 T cells.
Mechanistic Analysis of IL-33 and IL-12 Synergy on IFNγ Production by CD8 T Cells. We conducted a detailed analysis of the T-cell response to IL-33 and IL-12 stimulation. IFNγ production by in vivo-activated OT-I CD8 T cells was strictly dependent on the dosage of both IL-33 and IL-12 because reduction of either cytokine decreased IFNγ secretion (Fig. 3C) . However, a log-fold reduction of IL-33 concentration appeared to have a more dramatic effect on decreasing IFNγ production compared with that of IL-12 (Fig. 3C) . Next, to identify the order of action by each cytokine, 4-1BB and OX40-activated OT-I CD8 T cells (26) were first cultured with IL-12 followed by IL-33 or vice versa. We found that a 1-h incubation with IL-12 was sufficient to prime the CD8 T-cell response to IL-33 in the following 23 h (Fig. 3D) . Reversing the order of these cytokines failed to induce IFNγ production, suggesting that the bulk of IFNγ production was triggered by IL-33 stimulation (Fig. 3D) . Furthermore, the presence of a blocking antibody against ST2 diminished IFNγ production during OT-I CD8 T-cell culture with IL-33 + IL-12 (Fig. 3E , Left, first two columns), confirming that contact between IL-33 and its receptor is necessary for synergy. Specifically, the ST2 blockade achieved its effects during the IL-33 incubation time in an assay of 1 h for IL-12 followed by 23 h for IL-33 (Fig. 3E , Left, last three columns). Neither the addition of an isotype antibody nor the use of the anti-ST2 antibody with a different cytokine combination (IL-12 + IL-18) affected IFNγ production (Fig. 3E, Right) , confirming the specificity of the blockade. Thus, much like a T-cell costimulatory signal, IL-33 requires a prior signaling event in CD8 T cells to manifest its proinflammatory function.
Poly(I:C) Pretreatment and Blocking the ST2 Pathway Reduces Local
and Systemic Immune Effectors During Acute Lung Injury. Colonization of Staphylococcus aureus in nasal polyps and their production of enterotoxins are associated with allergic rhinitis and chronic sinusitis (27) . Our laboratory showed that intranasal (i.n.) SEA results in acute lung injury that depends on the activation of CD8 T cells and IFNγ, and importantly, this lung injury model also presents systemic effects (28) . We tested if systemic pretreatment with poly(I:C) could mitigate the local and systemic responses to i.n. SEA challenge. Two of the major cytokines found in bronchial-alveolar lavage (BAL) fluid at 2 d post i.n. SEA challenge were IL-5 and IFNγ ( Fig. 4A and Fig. S5 ). On the basis of our ex vivo data ( Figs. 1  and 3 ), the source of IFNγ was likely to be SEA-triggered T cells, through either TCR activation or IL-33 stimulation. On the contrary, the source of IL-5 is less clear. It is unlikely to be from Th2 cells because SEA elicits mainly Th1 responses (29) . However, we observed IL-4, IL-5, IL-13, and IL-10 in the BAL fluid after i.n. SEA (Fig. S5) , indicating that this route of SEA inoculation may induce Th2-type responses. Other airway allergy models indicate that IL-5 could be induced by IL-33 following antigen challenge (30) . We performed immunohistochemical staining of IL-33 on lung tissue 2 d after i.n. SEA and found that, indeed, IL-33 was expressed (Fig. 4B) . IL-33 may be responsible for IL-5 production in our model because IL-5 was not detected in IL-33 −/− mice after i.n. SEA challenge (Fig. 4C) . The presence of IL-33 and IL-5 could exacerbate airway inflammation by recruiting eosinophils and other innate immune cells (31, 32) . These and our previous reports suggest that considerable lung damage might be caused by both effector cytokines IL-5 and IFNγ. We showed here that either poly(I:C) pretreatment or blocking ST2 was sufficient to inhibit IL-5 production, but the administration of both proved most effective (Fig. 4A, Left) . Next, whereas poly(I:C) pretreatment did not significantly reduce IFNγ secretion into the BAL fluid, ST2 blocking was able to do so (Fig. 4A, Center) . Interestingly, when examining the influx of leukocytes into the BAL fluid, we observed that poly(I:C) and anti-ST2 antibody worked additively to reduce the presence of Gr-1 hi cells (Fig. 4A, Right) . Importantly, mice pretreated with poly(I:C) showed reduced systemic accumulation of effector T cells (Fig. 4 D and E) , suggesting that it could potentially limit bystander damage in the periphery caused by a septic response originating in the lung. Overall, these data indicate that poly(I:C), especially when aided by blocking the ST2 pathway, can reduce local and systemic toxicity.
Discussion
Like many other TLR ligands, poly(I:C) has routinely been used as an adjuvant, but others (33, 34) and this study (Fig. 1) have shown that prior exposure to poly(I:C) can inhibit CD8 T-cell responses. Two distinct mechanisms were put forth to explain these findings: First, naive CD8 T cells that were exposed to poly (I:C)-induced type I IFNs became refractory to Ag stimulation later (33) , and, second, TLR ligands can inhibit antigen cross presentation (34) , thereby impairing CD8 T-cell priming. In addition, the Welsh group showed that exposure to poly(I:C) affects CD8 effector differentiation and impacts the memory T cell pool (35, 36) . These studies highlight the danger of constant exposure to TLR ligands, in particular during chronic infection, coinfection, or sepsis, in mounting a robust CD8 T-cell response when the host encounters viral infection. However, a recent report using a panel of TLR ligands to suppress asthma and autoimmune diabetes suggested that microbial stimulation (typically with systemic administration of TLR ligands) could prevent allergies and autoimmunity, providing a plausible explanation for the hygiene hypothesis (37) . Hence, TLR ligands can have dual immunomodulating properties, and the suppressive nature of them could be damaging (impairing antiviral responses) or beneficial (preventing immune disorders). Historical data demonstrating the dual immuno-modulating properties of poly(I:C) include a classic model of graft-versus-host disease (38, 39) and autoimmune diabetes (13, 18) . Collectively, these results suggest that poly(I:C), and perhaps many other TLR ligands, may be able to both promote and dampen an immune response based on the timing, the magnitude, or the type of inflammation induced. Consequently, T-cell priming is affected. Our results show that one potential mechanism by which poly(I:C) dampens the immune response may be by restricting CD8 T-cell responses to IL-33.
It is known that IFNγ transcription in CD8 T effector cells can be activated by TCR stimulation (CD3 + CD28) and proinflammatory cytokines (IL-18 + IL-12 or IL-33 + IL-12) (25, 40) . Although synthesis of IFNγ after TCR triggering tends to be rapid (within 5 h), that from the IL-33/ST2 pathway requires more time (>20 h) (Fig. 1E and Fig. S4B ). It will be interesting to determine if these are the same subset of effector cells or different subpopulations. We found that the IL-33-dependent effector function of CD8 T cells was down-modulated by poly(I:C) pretreatment (Fig. 3A) . This finding is consistent with the observation that CD8 T cells expressed less ST2 after poly(I:C) pretreatment ( Fig.  2A) . Because both IL-33 and IL-18 are members of the IL-1 cytokine family and IL-33 is phylogenetically related to IL-18 (20) , it is possible that the synergy between IL-33 and IL-12 uses the same intracellular pathway as IL-18 and IL-12 to induce IFNγ production. Indeed, the signaling protein GADD45β, which is responsible for IL-18 and IL-12 synergy on CD4 T cells (41) , is involved in IL-33 and IL-12 synergy as well (25) . Further analysis using the IL-33R blockade showed that IL-33 + IL-12 synergy was achieved in a sequential manner, with IL-12 acting ahead of IL-33 (Fig. 3D) . Hence, during secondary TCR-independent stimulation of effector CD8 T cells, IL-12 acted as signal 1 and IL-33 as signal 2 for the induction of IFNγ synthesis. This sequence-dependent synergy on IFNγ release uncovers an aspect of the regulation of T-cell biology that awaits further investigation. Specifically, a thorough understanding of IL-12-triggered intracellular events within effector CD8 T cells is instrumental in deciphering their response to IL-33.
Altogether, we are beginning to recognize that once CD8 T cells are activated, their effector function is dictated not only by the availability of antigen, but also very much by the cytokine milieu. In addition to the above-mentioned inflammatory cytokines, which are often produced by innate immune cells, we further demonstrated that a T-cell-derived cytokine IL-2 is also capable of synergizing with IL-33 to stimulate CD8 T cells (Fig.  3B) . Similarly, this synergistic effect is impaired for T cells activated in poly(I:C)-pretreated mice (Fig. 3B) . These results suggested that, in a physiological setting, previously activated CD8 T cells may be stimulated nonspecifically by multiple cytokines during inflammation or secondary infections. Consequently, T cells may mediate tissue pathology when IL-33 is present, even when cognate antigen is absent. However, recent data demonstrated that, during primary antiviral responses, IL-33 mediates beneficial effects that support CD8 effector responses (24) . In the future, it will be important to examine the physiological impact of the CD8 T-cell response to IL-33 in different immunological settings to fully appreciate the benefits or damage related to this pathway.
Our findings showing that the biology of effector CD8 T cells can be fundamentally altered by a TLR ligand adds a perspective to the interpretation of the hygiene hypothesis. In particular, it contributes to the understanding of why CD8 T-cell-mediated autoimmune disease such as diabetes can be prevented by TLR ligands before disease onset in experimental animals (12) . On the other hand, our ST2 expression data on CD8 T cells (Fig. 2) and their responses to IL-33, IL-12, and IL-2 (Fig. 3) pinpointed a potential role of these cells in exacerbating tissue damage during proinflammatory responses where such cytokines are abundant. For example, IL-33 is associated with exacerbation of asthma, a widely studied airway inflammatory disorder (42) . Extrapolating from our results with CD8 T cells, it would be interesting to test if pre-exposure to TLR ligands could dampen ST2 expression on other inflammatory cells (such as Th2 cells, eosinophils, and mast cells) and, by extension, their IL-33-mediated effector function during airway inflammation.
The superantigen-mediated acute lung injury model that we used in this study shares some common features with other inflammatory airway diseases. SEA induces IL-33 expression in the lung and IL-5 production in the BAL fluid (Fig. 4 A-C) , and both cytokines are linked to pulmonary disease models (30, 31) . In addition, we also observed increased Gr-1 + cells in the BAL fluid, an event that associates with augmentation of airway allergy and recruitment of T helper cells to the airways (43) . Systemic preexposure to poly(I:C) or ST2 blockade suppressed IL-5 levels in BAL fluid (Fig. 4A, Left) , and the combination of both inhibited the accumulation of Gr1 hi cells in BAL (Fig. 4A, Right) . On the other hand, the pulmonary response to SEA is unique because effector T cells activated after insult in the lung could spread systemically. It may be argued that these effector T cells can instigate damage elsewhere in the body because they are now able to respond to the inflammatory cytokines IL-33 and IL-12.
Here we observed that the effector responses outside the lung were dampened in the poly(I:C)-pretreated mice (Fig. 4 D and E) , demonstrating a systemic immunoregulatory effect of poly(I:C) during an ongoing mucosal immune response.
In conclusion, we uncovered an unappreciated role of poly(I:C) and, on reflection, of double-stranded RNA, in the immune system. The suppressive effects presented here are what we would term an "exjuvant" effect of poly(I:C). Unlike its well-studied adjuvant effects, we showed that pretreatment with poly(I:C) could be exploited to thwart rather than to promote not only TCR-related effector T-cell responses, but also, and importantly, the newly discovered IL-33/ST2 responses that are widely implicated in mucosal inflammatory diseases. Thus, exploiting the timing of TLR ligand exposure is likely to provide much-needed clinical benefit for human diseases.
Materials and Methods
General sources of reagents, description of spleen, liver, lung, BAL fluid processing, flow cytometry, and immunohistochemical analysis can be found in SI Materials and Methods. IL-33 −/− mice were produced at Amgen using standard methodology and provided by D.E.S., whereas the wild-type controls were purchased from Taconic Farms Inc. The ST2-blocking monoclonal antibody and the rat IgG1 isotype control (anti-KLH, monoclonal) were also provided by D.E.S. (44) . The immunization procedures are described in SI Materials and Methods and include a description of in vivo stimulation of transferred OT-I cells and stimulation of endogenous T cells using SEA and SIINFEKL. The IL-33 ex vivo culture system, statistical analysis, and costimulation procedure are also described in the SI Materials and Methods.
